LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) said today that its IV antibiotic CUBICIN® (daptomycin for injection) is now approved for additional indications in the EU. These remarks were made by Michael W. Bonney, Cubist’s President and CEO, during a web cast at the Thomas Weisel Partners Healthcare Conference in Boston. The new EU approval, announced yesterday by Novartis, Cubist’s exclusive licensee in the EU and certain other parts of the world for marketing CUBICIN, is based on data from Cubist’s landmark Staphylococcus aureus (S. aureus) bacteremia and endocarditis trial.
